Amarin (AMRN) Corporation announced upcoming presentations at the European Society of Cardiology, ESC, Congress 2025, August 29th-September 1st, in Madrid, Spain, where new data will further illuminate the multifaceted cardioprotective effects of icosapent ethyl, IPE. Data to be featured at ESC 2025 will provide deeper insight into the potential role of IPE in reducing cardiovascular risk through multiple mechanisms, including effects on inflammation, lipoprotein oxidation, CV risk associated with CV-kidney-metabolic, CKM, syndrome, and risk and duration of hospitalizations. Highlights include new analyses from the REDUCE-IT trial evaluating the clinical benefit of IPE, alongside mechanistic studies investigating the impact of eicosapentaenoic acid, EPA, on inflammasome activation, lipoprotein oxidation, and pro-inflammatory protein expression in endothelial cells under conditions of oxidative stress.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRN: